Quarterly report pursuant to Section 13 or 15(d)

Note 12 - Stockholders' Equity

v3.22.1
Note 12 - Stockholders' Equity
 3 Months Ended
Mar. 31, 2022
Notes to Financial Statements  
Stockholders' Equity Note Disclosure [Text Block]

12. Stockholders’ Equity

 

Shares issued

 

During the three months ended March 31, 2022, the Company issued 1,099,177 shares of common stock upon vesting of Restricted Stock Units ("RSUs") granted by the Company to management and employees. 

 

During the three months ended March 31, 2022, the Company issued 20,471 shares of common stock upon vesting of RSUs granted to Board members.

 

During the three months ended March 31, 2022, the Company issued 3,397,999 shares of common stock pursuant to the At The Market Issuance Sales Agreement for net proceeds of $3.9 million.

 

Stock-based compensation

 

The stock-based compensation expense was allocated as follows:

 

   

Three Months Ended March 31,

  
   

2022

    

2021

  

Cost of product sales

   $ 25     $ 31  

Research and development cost

     18       42  

General and administrative expense

     562       606  

Total

   $ 605     $ 679  

 

There were no options issued during the three months ended March 31, 2022 or the three months ended March 31, 2021.

 

Restricted stock units

 

In January 2022, the Company granted 44,780 RSUs, all of which were subject to vesting, with a grant fair value of $50,000 to employees. The shares vest in three equal installments over a three-year period. No shares vested during the three months ended March 31, 2022.